aim
diagnost
microbiolog
commun
acquir
pneumonia
cap
provid
use
inform
patient
manag
infect
control
epidemiolog
surveil
newer
techniqu
enhanc
inform
time
interv
obtain
result
audit
diagnost
microbiolog
utilis
microbiolog
aetiolog
influenc
result
prescrib
practic
cap
region
australian
hospit
set
perform
method
clinic
microbiolog
outcom
data
collect
medic
record
review
patient
discharg
ballarat
hospit
diagnosi
cap
month
period
result
identifi
cap
episod
diagnost
microbiolog
perform
respiratori
viru
polymeras
chain
reaction
pcr
rare
perform
episod
acut
serolog
frequent
request
howev
pair
acut
convalesc
serolog
infrequ
perform
test
episod
cap
sever
correl
microbiolog
investig
intens
common
pathogen
identifi
streptococcu
pneumonia
mycoplasma
pneumonia
respect
diagnost
test
appear
rare
influenc
antimicrobi
prescrib
conclus
set
diagnost
microbiolog
test
respiratori
viru
pcr
urinari
antigen
test
underutilis
contrast
sputum
serolog
investig
commonli
request
howev
rare
influenc
practic
intervent
facilit
effici
usag
diagnost
microbiolog
requir
commun
acquir
pneumonia
cap
common
present
emerg
depart
frequent
reason
hospit
admiss
admit
patient
day
mortal
australian
hospit
vari
sever
local
intern
group
publish
guidelin
manag
cap
includ
use
antibiot
microbiolog
investig
underli
microbi
caus
cap
variou
popul
well
describ
howev
limit
data
avail
cap
australian
rural
set
ballarat
hospit
largest
hospit
grampian
region
victoria
servic
estim
peopl
spread
squar
kilomet
provid
acut
inpati
bed
servic
region
centr
ballarat
popul
month
retrospect
audit
cap
admiss
ballarat
hospit
conduct
assess
frequenc
investig
microbi
aetiolog
correspond
clinic
outcom
patient
record
patient
admit
ballarat
hospit
discharg
diagnosi
cap
octob
septemb
retriev
review
patient
meet
follow
criteria
includ
discharg
diagnosi
cap
clinic
syndrom
compat
cap
consolid
chest
radiographi
report
radiologist
age
year
patient
suspect
aspir
pneumonia
hospit
acquir
pneumonia
signific
immunosuppress
activ
treatment
malign
prior
organ
transplant
hiv
use
mg
prednisolon
per
day
previou
month
equival
immunosuppress
agent
transfer
anoth
healthcar
facil
exclud
paramet
allow
calcul
pneumonia
sever
index
psi
discharg
data
length
stay
antibiot
treatment
regimen
collect
avail
result
blood
cultur
sputum
microscopi
cultur
urinari
antigen
streptococcu
pneumonia
legionella
pneumophila
puat
luat
respect
nose
andor
throat
swab
respiratori
virus
acut
convalesc
serolog
respiratori
pathogen
record
hospit
patholog
system
ethic
approv
requir
retrospect
audit
microbiolog
investig
perform
per
treat
clinician
discret
refer
recommend
nation
guidelin
convent
techniqu
use
aerob
anaerob
blood
cultur
sputum
microscopi
cultur
signific
result
sputum
microscopi
cultur
record
follow
criteria
met
sampl
collect
within
h
admiss
predomin
neutrophil
microscopi
microscopi
cultur
concord
nose
andor
throat
swab
respiratori
virus
influenza
b
parainfluenza
picornaviru
respiratori
syncyti
viru
adenoviru
process
multiplex
polymeras
chain
reaction
pcr
previous
describ
serolog
mycoplasma
pneumonia
particl
agglutin
serodia
fujirebio
japan
l
pneumophila
immunofluoresc
l
pneumophila
serogroup
igg
qml
patholog
influenza
b
complement
fixat
victorian
infecti
diseas
refer
laboratori
vidrl
coxiella
burnetii
phase
ii
complement
fixat
vidrl
chlamydophila
group
serolog
elisa
seroelisa
savyon
diagnost
israel
speciat
immunofluoresc
requir
puat
binaxnow
pneumococc
urinari
antigen
detect
kit
luat
binaxnow
legionella
urinari
antigen
eia
kit
perform
unconcentr
urin
specimen
per
manufactur
instruct
aler
usa
proport
patient
microbiolog
investig
yield
proport
test
perform
return
posit
result
variou
test
express
percentag
associ
psi
number
test
perform
like
yield
caus
pathogen
assess
use
mannwhitney
u
test
pathogen
identifi
interpret
probabl
caus
pathogen
follow
criteria
met
cultur
organ
known
caus
cap
blood
cultur
posit
urinari
antigen
compat
sputum
cultur
microscopi
good
qualiti
sputum
specimen
defin
initi
antibodi
titr
pneumonia
rise
acut
convalesc
phase
pneumonia
l
pneumophila
chlamydophila
speci
influenza
ab
elev
c
burnetii
phase
antibodi
igg
igm
detect
respiratori
viru
pcr
nose
throat
swab
microbiolog
investig
determin
influenc
antibiot
prescrib
antibiot
spectrum
chang
target
identifi
pathogen
data
collect
analysi
perform
use
microsoft
excel
microsoft
usa
stata
version
statacorp
usa
month
period
episod
cap
identifi
patient
patient
record
review
patient
episod
cap
meet
inclus
criteria
main
reason
exclus
absenc
radiolog
chang
suspect
aspir
hospit
acquir
pneumonia
immunosuppress
malign
includ
patient
complet
clinic
data
allow
determin
psi
length
stay
inhospit
mortal
avail
cohort
median
age
year
inhospit
mortal
rate
psi
class
cap
intens
care
unit
icu
high
depend
unit
hdu
admiss
rate
day
median
length
stay
psi
distribut
across
class
respect
microbiolog
investig
perform
patient
episod
median
one
investig
perform
per
episod
interquartil
rang
iqr
investig
intens
mild
moder
psi
moder
sever
psi
cap
median
number
investig
per
cap
episod
iqr
iqr
respect
mannwhitney
test
z
p
blood
cultur
taken
nearli
episod
common
microbiolog
investig
wherea
assess
respiratori
virus
rare
undertaken
episod
fig
use
respiratori
viru
pcr
puat
luat
particularli
low
psi
cap
respect
episod
least
one
probabl
caus
pathogen
identifi
episod
common
pathogen
identifi
pneumonia
pneumonia
tabl
one
patient
pneumonia
detect
sputum
analysi
puat
anoth
patient
simultan
detect
haemophilu
influenza
moraxella
catarrhali
sputum
overal
episod
least
one
microbiolog
investig
perform
probabl
caus
pathogen
identifi
yield
confid
interv
commonli
perform
test
follow
blood
cultur
ci
luat
ci
sputum
mc
ci
puat
ci
mycoplasma
serolog
ci
respiratori
viru
pcr
appear
highest
yield
microbiolog
investig
ci
howev
low
utilis
compromis
interpret
low
test
utilis
limit
signific
yield
calcul
investig
yield
microbiolog
investig
accord
psi
associ
psi
sever
psi
yield
per
test
compar
psi
yield
mannwhitney
test
z
p
number
episod
probabl
caus
pathogen
identifi
insuffici
make
comparison
pathogen
mortal
length
stay
episod
probabl
caus
pathogen
identifi
episod
result
avail
within
clinic
use
timefram
prior
discharg
death
complet
prescrib
antibiot
cours
howev
one
patient
result
avail
postmortem
blood
cultur
grow
methicillin
resist
staphylococcu
aureu
six
episod
probabl
caus
pathogen
identifi
result
appear
influenc
antibiot
prescrib
remain
case
broadspectrum
combin
antimicrobi
continu
largest
studi
microbi
aetiolog
cap
australia
like
pathogen
identifi
episod
studi
microbi
aetiolog
cap
variou
set
identifi
pathogen
patient
much
diagnost
variat
account
intens
investig
studi
set
thu
pathogen
identif
rate
studi
unexpect
given
invas
diagnost
method
employ
studi
retrospect
audit
clinic
practic
streptococcu
pneumonia
commonli
identifi
pathogen
reflect
find
similar
studi
pneumonia
less
frequent
identifi
pathogen
cap
compar
histor
studi
mycoplasma
pneumonia
next
frequent
pathogen
although
well
known
pneumonia
rate
vari
significantli
epidem
occur
approxim
everi
year
three
episod
aureu
cap
one
episod
escherichia
coli
cap
identifi
although
previous
report
pathogen
unusu
caus
cap
may
reflect
inaccuraci
case
ascertain
overal
rel
rate
variou
pathogen
similar
temper
australian
intern
studi
diagnost
microbiolog
investig
cap
controversi
blood
sputum
cultur
avail
recommend
certain
clinic
criteria
met
eg
patient
icu
moder
sever
cap
cavit
lesion
failur
outpati
therapi
presenc
pleural
effus
serolog
studi
pneumonia
chlamydophila
speci
legionella
speci
influenza
use
epidemiolog
data
wherea
investig
respiratori
viru
pcr
urinari
antigen
test
provid
time
result
may
directli
impact
patient
care
studi
least
moder
sever
cap
psi
class
median
number
microbiolog
investig
perform
per
patient
episod
low
one
per
episod
moder
sever
cap
episod
blood
cultur
collect
sputum
collect
compar
prior
studi
lack
fever
prior
antibiot
administr
may
explain
low
blood
cultur
collect
rate
howev
data
collect
blood
cultur
limit
sensit
cap
excel
specif
contamin
exclud
greater
util
abil
provid
prognost
inform
facilit
monitor
antimicrobi
suscept
profil
invas
pathogen
allow
detect
unexpect
bacteraemia
eg
infect
endocard
import
pathogen
eg
aureu
pseudomona
aeruginosa
provid
clue
identifi
patient
underli
predispos
condit
eg
pneumococc
bacteraemia
hiv
hyposplen
studi
blood
cultur
yield
low
howev
posit
cultur
appear
provid
prognost
inform
bacteraem
patient
surviv
discharg
dictat
chang
antimicrobi
prescrib
patient
methicillin
resist
aureu
patient
methicillin
sensit
aureu
requir
target
therapi
thu
blood
cultur
collect
recommend
hospitalis
patient
moder
sever
cap
irrespect
patient
temperatur
sputum
microscopi
cultur
avail
patient
unabl
produc
appropri
sputum
sampl
limit
sensit
specif
studi
sputum
collect
cap
episod
posit
yield
lower
previous
report
possibl
relat
stricter
sputum
analysi
criteria
sputum
identifi
like
pathogen
episod
appear
influenc
antimicrobi
prescrib
two
episod
episod
sputum
collect
sputum
analysi
noninvas
rel
cheap
potenti
influenc
patient
manag
allow
epidemiolog
surveil
cap
pathogen
associ
antimicrobi
suscept
howev
limit
includ
inher
poor
specif
difficulti
detect
pathogen
pneumonia
legionella
speci
chlamydophila
speci
given
low
rate
influenc
sputum
diagnost
could
argu
sputum
collect
avoid
mild
moder
cap
unless
clinic
suspicion
resist
unusu
pathogen
eg
aureu
p
aeruginosa
mycobacteria
speci
nocardia
speci
acinetobact
baumanii
burkholderia
pseudomallei
failur
respond
therapi
patient
underw
test
respiratori
virus
moder
sever
cap
account
low
rate
respiratori
viru
identif
respiratori
virus
becom
increasingli
recognis
caus
cap
identif
allow
therapeut
intervent
accur
implement
infect
control
practic
also
inform
vaccin
public
health
polici
provid
valuabl
support
evid
vaccin
patient
staff
possibl
explan
low
test
rate
includ
perceiv
lack
therapeut
intervent
moder
influenza
activ
studi
period
perceiv
delay
receipt
result
due
specimen
referr
extern
laboratori
given
recent
pandem
influenza
increas
diagnost
test
influenza
pneumonia
may
expect
addit
rel
recent
multiplex
respiratori
viru
nucleic
acid
amplif
test
floccul
swab
nasopharynx
becom
readili
avail
absolut
yield
respiratori
viru
pcr
limit
studi
due
low
utilis
publish
studi
demonstr
yield
respiratori
viru
pcr
cap
rel
high
cap
investig
thu
test
recommend
inpati
moder
sever
cap
clinic
epidemiolog
featur
suggest
viral
aetiolog
particularli
season
peak
import
caveat
although
molecular
techniqu
respiratori
virus
report
increas
microbiolog
diagnost
sensit
cap
signific
detect
pathogen
coronavirus
rhinovirus
remain
uncertain
addit
test
smaller
centr
may
associ
signific
cost
time
delay
due
specimen
referr
moder
sever
cap
luat
puat
perform
urin
commonli
avail
test
sputum
rapid
turn
around
time
greater
sensit
specif
sputum
urinari
antigen
studi
prefer
investig
option
moder
sever
cap
disadvantag
includ
lack
antimicrobi
suscept
inform
cost
limit
serotyp
detect
luat
l
pneumophila
serotyp
reliabl
detect
account
commun
acquir
legionella
addit
yield
puat
luat
low
respect
nevertheless
posit
result
allow
antibiot
rationalis
may
limit
diagnost
test
facilit
earli
detect
legionella
outbreak
studi
pair
acut
convalesc
serolog
evalu
rare
perform
instanc
acut
serolog
perform
convalesc
serolog
perform
asid
pneumonia
igm
test
isol
evalu
acut
serolog
sampl
rare
help
mislead
ration
approach
would
store
acut
sampl
await
convalesc
sampl
test
parallel
yield
serolog
test
highest
pneumonia
howev
specif
singl
antibodi
titr
definit
use
studi
recommend
manufactur
criticis
serolog
test
remain
vital
pathogen
identif
via
mean
limit
eg
pneumonia
chlamydophila
speci
c
burnetti
howev
molecular
techniqu
improv
diagnost
accuraci
time
local
avail
cost
restrict
widespread
implement
techniqu
given
limit
serolog
studi
littl
influenc
antimicrobi
prescrib
would
expect
support
studi
antimicrobi
prescrib
appear
influenc
one
serolog
test
perform
summaris
controversi
tabl
provid
recommend
diagnost
microbiolog
cap
recommend
adapt
local
intern
guidelin
incorpor
find
studi
facilit
implement
ensur
sustain
utilis
propos
develop
local
clinic
pathway
clinic
pathway
improv
adher
treatment
guidelin
although
assess
impact
investig
utilis
part
bundl
care
limit
studi
number
import
limit
singl
centr
retrospect
audit
find
need
cautious
appli
popul
group
local
guidelin
practic
may
influenc
util
diagnost
investig
antimicrobi
prescrib
also
limit
generalis
low
overal
number
limit
diagnost
util
especi
respiratori
viru
pcr
may
compromis
find
psi
known
number
limit
thu
use
psi
studi
correl
sever
inher
restrict
sputum
routin
cultur
legionella
sp
serolog
nonpneumophila
legionella
speci
perform
shown
import
contributor
cap
australia
evalu
uncommon
cap
pathogen
assess
eg
mycobacterium
tuberculosi
fungal
pathogen
nocardia
speci
bordetella
pertussi
strict
criteria
appli
sputum
analysi
may
underestim
diagnost
util
henc
influenc
antibiot
manag
costbenefit
analysi
investig
perform
studi
demonstr
microbiolog
cap
region
set
mirror
cap
temper
set
studi
also
demonstr
routin
clinic
practic
microbiolog
investig
particularli
respiratori
viru
pcr
urinari
antigen
underutilis
especi
admit
patient
moder
sever
cap
diagnost
yield
blood
cultur
low
posit
result
strongli
influenc
manag
provid
import
prognost
inform
investig
serolog
test
sputum
studi
appear
limit
impact
patient
manag
due
poor
specif
could
reserv
specif
clinic
situat
increas
clinician
awar
modern
microbiolog
techniqu
assess
patient
cap
incorpor
cap
clinic
pathway
may
lead
improv
effici
utilis
resourc
includ
mycoplasma
sp
chlamydophila
sp
legionella
sp
influenza
q
fever
rarer
caus
cap
epidemiolog
risk
factor
may
prompt
serolog
evalu
blood
serolog
least
store
sever
cap
convalesc
sampl
collect
need
basi
includ
bronchoscopi
bronchoalveolar
lavag
investig
mycobacterium
tuberculosi
molecular
techniqu
mycoplasma
sp
legionella
sp
chlamydophila
sp
pneumocysti
jiroveci
fungal
pathogen
nr
gener
recommend
option
pcr
polymeras
chain
reaction
r
gener
recommend
uat
urinari
antigen
test
mc
microscopi
cultur
